Flashcards in 7.20 Agents of Viral Hepatitis Deck (44)
Loading flashcards...
1
Infectious hepatitis
HAV
2
Serum hepatitis
HBV
3
Post-transfusion hepatitis
HCV
4
Enterically transmitted hepatitis
HEV
5
Picornaviridae
Icosahedral
ssRNA
Fecal oral
HAV
6
Autoclaving
HAV
7
Principal age distribution
Children
Young adults
8
Abrupt onset
Elevated IgM
No complication
Confers immunity
HAV
9
Detectable at onset of symptoms
Lifetime persistence
Anti-HAV
10
Indicates recent infection with HAV
4-6 months after infection
IgM anti-HAV
11
Gold standard for diagnosing hepatitis
HAV IgM
12
Highest rate of HAV incidence is between:
5-14
13
HAV immunity
2 doses
14
Hepadnaviridae
Spherical
dsDNA circular
Acid-sensitive
Chronic disease
Oncogenic
HBV
15
Made up exclusively of HBsAg
Spherical
16
Less frequently observed
Dane particles
17
Made up exclusively of HBsAg
Tubular or filamentous
18
Four phenotypes of HBsAg
adw (predominant), ayw, adr, ayr
19
Template for production of HBV mRNAs and RNA pre-genome
ccDNA
20
Predominant route of HBV infection
Parenteral
21
More extensive damage which prevents orderly liver cell regeneration
Acute viral hepatitis
22
Mild benign disease that may follow acute HBV infection
Persistent unresolved viral hepatitis
23
Histologic changes include inflammation and necrosis to collapse of the normal reticulum framework with bridging between portal triads or terminal hepatic veins
Chronic active hepatitis
24
Most useful detection methods for HB
ELISA for HBV Ag and Ab
PCR viral DNA
25
Occur early in the incubation period
DNA pol, HBV DNA, HBeAg
26
Associated with recovery from infection
Persists for more than 6 months in the presence of HBeAg
HBsAg
27
Detected at the onset of clinical illness
Indicative of viral replication
IgM-specific anti-HBc
28
Adults infected with HBV are at high risk of developing ____
HCC
29
First line therapies for HBV
Pegylated IFN alfa-2a
Entecavir
Tenofovir
30
Guanosine analogue inhibitor of HBV polymerase
Entecavir
31
Nucleotide analogue inhibitor of HBV reverse transcriptase and polymerase
Tenofovir
32
Second line therapies for HBV
Telbivudine
33
Cytosine nucleoside analogue
Inh of HBV DNA pol
Telbivudine
34
Third line therpay for HBV
Lamivudine
Adenofovir
35
Nucleoside analog viral polymerase inhibitors
Lamivudine
Adenofovir
36
Flaviviridae
Spherical
(+) stranded ssRNA
Chronic disease
Oncogenic
HCV
37
HCV treatment
Pegylated IFN + ribavirin
38
First generation protease inhibitor drugs
Target the viral protease, which cleaves the translated viral polypeptide into functional proteins
Telaprevir
Boceprevir
39
Second generation HCV antivirals
Sofosbuvir
Simepravir
40
Nucleotide analog HCV viral RNA inhibitor
Sofosbuvir
41
HCV protease inhibitor
Simepravir
42
Unclassified
Envelope- HBsAg
ssRNA, negative sense, circular
Parenteral
Smalles known human antigen
Not sexually transmitted
HDV
43
Only protein encoded for by HDV RNA
HDAg
44
